Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Carnival secures new $4.5bn revolving credit facility

(Sharecast News) - Carnival announced on Monday that it has secured a new $4.5bn multi-currency revolving credit facility, extending its access to liquidity through to June 2030. The FTSE 250 cruise operator said the new facility replaced an existing revolving credit line held by subsidiary Carnival Holdings Bermuda II.

It said the arrangement included an accordion feature allowing the facility to be increased by up to $1bn in additional revolving commitments.

The new credit line was unsecured, and would initially be guaranteed on an unsecured basis by the same subsidiaries that backed Carnival's senior secured term loan facilities.

Both Carnival Corporation and Carnival plc were participating as borrowers under the agreement, which was arranged with a global syndicate of financial institutions.

JPMorgan Chase Bank was acting as administrative agent.

"This 50% increase in our revolver meaningfully enhances our liquidity, providing opportunities to continue accelerating our debt reduction efforts," said chief financial officer David Bernstein.

"Securing this significant upsize and extension to our revolver, on more favorable terms, also reflects confidence in our continued performance and achieves another milestone toward rebuilding our financial fortress."

At 1007 BST, shares in Carnival were up 1.5% at 1,526p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.